Related Experiment Video
Updated: Aug 16, 2026

Assessment of Vascular Function in Patients With Chronic Kidney Disease
Published on: June 16, 2014
Qualification of arterial stiffness as a risk factor to the progression of chronic kidney diseases
Tsuneo Takenaka1, Taku Mimura, Yoshihiko Kanno
1Department of Nephrology, Saitama Medical College, 38 Moro-hongo Moroyama, Iruma Saitama 350-0495, Japan.
Insights
Augmentation index (AI), a measure of arterial stiffness, is linked to worsening non-diabetic chronic kidney disease (CKD) and left ventricular hypertrophy. Higher AI indicates increased risk for CKD progression.
Area of Science:
- Cardiovascular Medicine
- Nephrology
- Biomedical Engineering
Background:
- Arterial stiffness, assessed by augmentation index (AI), may impact chronic kidney disease (CKD) progression.
- The specific relationship between AI and non-diabetic CKD progression requires further characterization.
Purpose of the Study:
- To investigate the association between augmentation index (AI) and the progression of non-diabetic chronic kidney diseases (CKDs).
- To explore the role of AI in the development of left ventricular hypertrophy in patients with non-diabetic CKD.
Main Methods:
- Pulse wave analysis was used to determine AI in 99 patients with non-diabetic CKDs.
- Echocardiography was performed in 51 patients to assess left ventricular mass index.
- Creatinine clearance was measured repeatedly in 41 patients to monitor CKD progression.
Main Results:
- AI positively correlated with age and weight, and negatively with height and heart rate (R(2) = 0.50).
- Elevated AI was associated with increased left ventricular mass index in male patients under angiotensin inhibition (r = 0.33, p < 0.05).
- Higher baseline AI predicted a greater annual decrease in creatinine clearance in patients on angiotensin inhibition (r = -0.52, p < 0.01).
Conclusions:
- Augmentation index (AI) and angiotensin contribute to left ventricular hypertrophy.
- AI is identified as a risk factor for the progression of non-diabetic CKDs, independent of angiotensin.
- These findings highlight AI as a potential therapeutic target in managing non-diabetic CKD.
Background:
Reflection pressure may influence the clinical course of chronic kidney diseases (CKDs). The relationship between the augmentation index (AI) and progression of non-diabetic CKDs was characterized.
Methods:
Ninety-nine patients were enrolled into the study. Pulse wave form analysis was performed to determine AI that assesses arterial stiffness.
Results:
In a cross-sectional study, a multiple regression analysis found that AI correlated positively to age and weight, and negatively to height and heart rate (R(2) = 0.50). Furthermore, echocardiography was performed in 51 patients who gave their consent. In male patients under angiotensin inhibition, left ventricular mass index increased as AI was elevated (r = 0.33, slope = 0.85 +/- 0.30 g/m(2)/%, p < 0.05, n = 23). A prospective study was performed in 41 patients who consented to having their creatinine clearance measured repeatedly. In the patients with angiotensin inhibition a higher basal AI resulted in a greater annual decrease in creatinine clearance (r = -0.52, slope = -0.43 +/- 0.14 ml/min/year/%, p < 0.01, n = 27).
Conclusion:
The present data indicate that AI as well as angiotensin contribute to the development of left ventricular hypertrophy. Furthermore, our results suggest that in addition to angiotensin, AI is a risk factor of progression of non-diabetic CKDs.
Related Concept Videos
Chronic Kidney Disease I: Introduction
Chronic Kidney Disease III: Interprofessional Care
Chronic Kidney Disease II: Clinical Manifestations
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
Chronic Kidney Disease IV: Nursing Management
Acute Kidney Injury IV: Diagnostic Studies and Prevention
